{"protocolSection":{"identificationModule":{"nctId":"NCT05074810","orgStudyIdInfo":{"id":"VS-6766-203"},"organization":{"fullName":"Verastem, Inc.","class":"INDUSTRY"},"briefTitle":"Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients","officialTitle":"A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Sotorasib With or Without Defactinib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)","acronym":"RAMP203"},"statusModule":{"statusVerifiedDate":"2026-01","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-04-12","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-06","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-04","type":"ESTIMATED"},"studyFirstSubmitDate":"2021-09-29","studyFirstSubmitQcDate":"2021-09-29","studyFirstPostDateStruct":{"date":"2021-10-12","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-01-08","lastUpdatePostDateStruct":{"date":"2026-01-12","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Verastem, Inc.","class":"INDUSTRY"},"collaborators":[{"name":"Amgen","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with sotorasib with or without defactinib in patients with KRAS G12C Non-Small Cell Lung Cancer (NSCLC) in patients who have been exposed to prior G12C inhibitor and those who have not been exposed to prior G12C inhibitor.","detailedDescription":"This is a multicenter, non-randomized, open-label Phase 1/2 study designed to evaluate safety and tolerability and efficacy of avutometinib (VS-6766) in combination with sotorasib with or without defactinib in patients with KRAS G12C mutant NSCLC."},"conditionsModule":{"conditions":["Non Small Cell Lung Cancer","KRAS Activating Mutation"],"keywords":["NSCLC","KRAS G12C"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"SEQUENTIAL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":153,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"avutometinib (VS-6766)+sotorasib","type":"EXPERIMENTAL","description":"To determine the recommended phase 2 dose (RP2D) for avutometinib (VS 6766) in combination with sotorasib in KRAS G12C inhibitor naïve and exposed patients","interventionNames":["Drug: avutometinib and sotorasib"]},{"label":"avutometinib (VS-6766)+sotorasib - KRAS G12C inhibitor naïve","type":"EXPERIMENTAL","description":"To determine the efficacy of the RP2D identified from Part A in KRAS G12C inhibitor naïve patients","interventionNames":["Drug: avutometinib and sotorasib"]},{"label":"avutometinib (VS-6766)+sotorasib - KRAS G12C inhibitor exposed","type":"EXPERIMENTAL","description":"To determine the efficacy of the RP2D identified from Part A in KRAS G12C inhibitor exposed patients","interventionNames":["Drug: avutometinib and sotorasib"]},{"label":"avutometinib (VS-6766)+sotorasib+defactinib","type":"EXPERIMENTAL","description":"To determine the recommended phase 2 dose (RP2D) for avutometinib (VS-6766) in combination with sotorasib and defactinib in KRAS G12C inhibitor exposed patients","interventionNames":["Drug: avutometinib and sotorasib and defactinib"]},{"label":"avutometinib (VS-6766)+sotorasib+defactinib - KRAS G12C inhibitor naive","type":"EXPERIMENTAL","description":"To determine the efficacy of the RP2D identified from Part A in KRAS G12C inhibitor naïve patients","interventionNames":["Drug: avutometinib and sotorasib and defactinib"]},{"label":"avutometinib (VS-6766)+sotorasib+defactinib - KRAS G12C inhibitor exposed","type":"EXPERIMENTAL","description":"To determine the efficacy of the RP2D identified from Part A in KRAS G12C inhibitor exposed patients","interventionNames":["Drug: avutometinib and sotorasib and defactinib"]}],"interventions":[{"type":"DRUG","name":"avutometinib and sotorasib","description":"The RP2D of avutometinib + sotorasib determined in Part A will be used in Part B dose expansion","armGroupLabels":["avutometinib (VS-6766)+sotorasib","avutometinib (VS-6766)+sotorasib - KRAS G12C inhibitor exposed","avutometinib (VS-6766)+sotorasib - KRAS G12C inhibitor naïve"],"otherNames":["AMG 510","LUMAKRAS™","VS-6766"]},{"type":"DRUG","name":"avutometinib and sotorasib and defactinib","description":"The RP2D of avutometinib + sotorasib + defactinib determined in Part A will be used in Part B dose expansion","armGroupLabels":["avutometinib (VS-6766)+sotorasib+defactinib","avutometinib (VS-6766)+sotorasib+defactinib - KRAS G12C inhibitor exposed","avutometinib (VS-6766)+sotorasib+defactinib - KRAS G12C inhibitor naive"],"otherNames":["AMG 510","LUMAKRAS™","VS-6766","VS-6063"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Part A: To determine RP2D for avutometinib in combination with sotorasib and the Alt-RP2D for avutometinib in combination with sotorasib and defactinib","description":"Assessment of Dose-limiting toxicities (DLTs)","timeFrame":"From start of treatment to confirmation of RP2D; 28 days"},{"measure":"Part B: To determine the efficacy of the RP2D and/or Alt-RP2D identified from Part A","description":"Confirmed overall response rate per RECIST 1.1","timeFrame":"From start of treatment to confirmation of response; 16 weeks"}],"secondaryOutcomes":[{"measure":"Frequency and severity adverse events (AEs) and Serious Adverse Events (SAEs)","description":"Count of AE and SAEs by grade, based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) grading scale","timeFrame":"24 months"},{"measure":"Duration of Response (DOR)","description":"Time of first response to PD as assessed per RECIST 1.1","timeFrame":"Time from the first documentation of response to first documentation of progressive disease or death due to any cause, greater than or equal to 6 months"},{"measure":"Disease Control Rate (DCR)","description":"CR and PR stable disease as assessed per RECIST 1.1","timeFrame":"Greater than or equal to 8 weeks"},{"measure":"Progression Free Survival (PFS)","description":"From the time of first dose of study intervention to PD or death from any cause","timeFrame":"24 months"},{"measure":"Overall Survival (OS)","description":"From time of first dose of study intervention to death","timeFrame":"Up to 5 years"},{"measure":"Plasma Pharmacokinetics (PK) of avutometinib, sotorasib, defactinib and relevant metabolites - Tmax","description":"time of Maximum concentration (Tmax)","timeFrame":"10 weeks"},{"measure":"Plasma Pharmacokinetics (PK) of avutometinib, sotorasib, defactinib and relevant metabolites -AUC","description":"Area under plasma Concentration (AUC) 0 to t","timeFrame":"10 weeks"},{"measure":"Plasma Pharmacokinetics (PK) of avutometinib, sotorasib, defactinib and relevant metabolites half-life","description":"concentration Half-life (T1/2)","timeFrame":"10 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female patients ≥ 18 years of age\n* Histologic or cytologic evidence of NSCLC\n* Known KRAS G12C mutation\n* Either exposed or not exposed to a KRAS inhibitor to be included in Part A (avutometinib + sotorasib + defactinib) and not exposed to KRAS inhibitor to be included in Part B (avutometinib + sotorasib + defactinib), Cohort 1\n* Received at least 1 dose of a G12C inhibitor to be included in Part B, Cohort 2 (avutometinib + sotorasib + defactinib)\n* Must have received appropriate treatment with at least one prior systemic regimen, but no more than 2 prior regimens, for Stage 3B-C or 4 NSCLC\n* Measurable disease according to RECIST 1.1\n* An Eastern Cooperative Group (ECOG) performance status ≤ 1\n* Adequate organ function\n* Adequate recovery from toxicities related to prior treatments\n* Agreement to use highly effective method of contraceptive\n\nExclusion Criteria:\n\n* Systemic anti-cancer therapy within 4 weeks of the first dose of study therapy\n* History of prior malignancy, with the exception of curatively treated malignancies\n* Major surgery within 4 weeks, minor surgery within 2 weeks (excluding placement of vascular access)\n* History of treatment with a direct and specific inhibitor of MEK\n* Exposure to strong CYP3A4 inhibitors or inducers within 14 days prior to the first dose and during the course of therapy\n* Symptomatic brain metastases requiring steroids or other local interventions.\n* Known SARS-Cov2 infection ≤28 days prior to first dose of study therapy\n* Known hepatitis B, hepatitis C, or human immunodeficiency virus infection that is active\n* Active skin disorder that has required systemic therapy within the past year\n* History of rhabdomyolysis\n* Concurrent ocular disorders\n* Concurrent heart disease or severe obstructive pulmonary disease\n* Inability to swallow oral medications\n* Female patients that are pregnant or breastfeeding\n* Previously treated with sotorasib and were dose reduced due to toxicity","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"MD Verastem","affiliation":"Verastem, Inc.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Rocky Mountain Cancer Center, LLP","city":"Boulder","state":"Colorado","zip":"80303","country":"United States","geoPoint":{"lat":40.01499,"lon":-105.27055}},{"facility":"Georgetown University Medical Center","city":"Washington D.C.","state":"District of Columbia","zip":"20007","country":"United States","geoPoint":{"lat":38.89511,"lon":-77.03637}},{"facility":"MedStar Washington Hospital Center, MedStar Georgetown Cancer Institute,","city":"Washington D.C.","state":"District of Columbia","zip":"20010","country":"United States","geoPoint":{"lat":38.89511,"lon":-77.03637}},{"facility":"Illinois Cancer Specialists","city":"Arlington Heights","state":"Illinois","zip":"60005","country":"United States","geoPoint":{"lat":42.08836,"lon":-87.98063}},{"facility":"Maryland Oncology & Hematology, P.A.","city":"Rockville","state":"Maryland","zip":"20850","country":"United States","geoPoint":{"lat":39.084,"lon":-77.15276}},{"facility":"Dana Farber Cancer Institute","city":"Boston","state":"Massachusetts","zip":"02215","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Henry Ford Health System","city":"Detroit","state":"Michigan","zip":"48202","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Minnesota Oncology Hematology, P.A","city":"Woodbury","state":"Minnesota","zip":"55125","country":"United States","geoPoint":{"lat":44.92386,"lon":-92.95938}},{"facility":"Washington University School of Medicine","city":"St Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Cleveland Clinic Taussig Cancer Center","city":"Cleveland","state":"Ohio","zip":"44195","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Ohio State University Brain and Spine Hospital","city":"Columbus","state":"Ohio","zip":"43210","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Consultants in Medical Oncology & Hematology","city":"Broomall","state":"Pennsylvania","zip":"19008","country":"United States","geoPoint":{"lat":39.9815,"lon":-75.35658}},{"facility":"Alliance Cancer Specialists,","city":"Horsham","state":"Pennsylvania","zip":"19044","country":"United States","geoPoint":{"lat":40.17844,"lon":-75.12851}},{"facility":"Texas Oncology","city":"Austin","state":"Texas","zip":"78731","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"University of Texas Southwestern Medical Center","city":"Dallas","state":"Texas","zip":"75390","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Texas Oncology - Fort Worth Cancer Center","city":"Fort Worth","state":"Texas","zip":"76104","country":"United States","geoPoint":{"lat":32.72541,"lon":-97.32085}},{"facility":"Texas Oncology","city":"Longview","state":"Texas","zip":"75601","country":"United States","geoPoint":{"lat":32.5007,"lon":-94.74049}},{"facility":"Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care","city":"Blacksburg","state":"Virginia","zip":"24060","country":"United States","geoPoint":{"lat":37.22957,"lon":-80.41394}},{"facility":"Virginia Cancer Specialists, PC","city":"Fairfax","state":"Virginia","zip":"22031","country":"United States","geoPoint":{"lat":38.84622,"lon":-77.30637}},{"facility":"Northwest Cancer Specialists","city":"Vancouver","state":"Washington","zip":"98684","country":"United States","geoPoint":{"lat":45.63873,"lon":-122.66149}},{"facility":"University Hospital Gent","city":"Ghent","zip":"9000","country":"Belgium","geoPoint":{"lat":51.05,"lon":3.71667}},{"facility":"CHU de Liège","city":"Liège","zip":"4000","country":"Belgium","geoPoint":{"lat":50.63373,"lon":5.56749}},{"facility":"CHRU of Lille","city":"Lille","zip":"59037","country":"France","geoPoint":{"lat":50.63391,"lon":3.05512}},{"facility":"Hôpital Cochin","city":"Paris","zip":"75014","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Hôpital Foch","city":"Suresnes","zip":"92150","country":"France","geoPoint":{"lat":48.87143,"lon":2.22929}},{"facility":"Leids Universitair Medisch Centrum","city":"Leiden","zip":"2333 ZA","country":"Netherlands","geoPoint":{"lat":52.15833,"lon":4.49306}},{"facility":"Erasmus MC","city":"Rotterdam","zip":"3015 GD","country":"Netherlands","geoPoint":{"lat":51.9225,"lon":4.47917}},{"facility":"Hospital Teresa Herrera (C.H.U.A.C)","city":"A Coruña","zip":"15006","country":"Spain","geoPoint":{"lat":43.37135,"lon":-8.396}},{"facility":"Hospital General Universitario Gregorio Marañón","city":"Madrid","zip":"28007","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitario Fundación Jiménez Díaz","city":"Madrid","zip":"28040","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitario Virgen De La Victoria","city":"Málaga","zip":"29010","country":"Spain","geoPoint":{"lat":36.72016,"lon":-4.42034}},{"facility":"Hospital Universitario Virgen de la Macarena","city":"Seville","zip":"41009","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"University of Leicester","city":"Leicester","zip":"LE2 7LX","country":"United Kingdom","geoPoint":{"lat":52.6386,"lon":-1.13169}},{"facility":"Royal Marsden Hospital","city":"London","zip":"SW3 6JJ","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Royal Marsden Hospital","city":"Sutton","zip":"SM2 5PT","country":"United Kingdom","geoPoint":{"lat":51.35,"lon":-0.2}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000706028","term":"sotorasib"},{"id":"C584510","term":"defactinib"}]}},"hasResults":false}